CORE LABORATORIES INC. 2023-2024 Proxy Voting Records

Description as filed by funds: To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified: Kwaku Temeng

CORE LABORATORIES INC.’s own tally for this item (“Elect Director: Kwaku Temeng”): 33,030,809 for, 5,285,742 withheld, per its Form 8-K filed May 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 21,469,928 for, 1,896,061 withheld.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified: Lawrence Bruno

CORE LABORATORIES INC.’s own tally for this item (“Elect Director: Lawrence Bruno”): 37,354,023 for, 962,528 withheld, per its Form 8-K filed May 10, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 23,322,326 for, 43,663 withheld.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: TO APPROVE AND RESOLVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2020 LONG-TERM INCENTIVE PLAN, THE PRINCIPAL PURPOSES OF WHICH ARE TO (I) INCREASE THE NUMBER OF SHARES AUTHORIZED THEREUNDER AND (II) EXTEND THE TERM OF SUCH PLAN THROUGH MAY 8, 2034.

CORE LABORATORIES INC.’s own tally for this item (“4. Approving the Amendment of the Company's Long-Term Incentive Plan: The amendment and restatement of the Company's 2020 Long-Term Incentive Plan, the principal purposes of which are to (i) increase the number of shares”): 36,742,268 for, 1,468,975 against — passed, per its Form 8-K filed May 10, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 – Approving the Amendment of the Company's Long-Term Incentive Plan : The amendment and restatement of the Company's 2020 Long-Term Incentive Plan, the principal purposes of which are to (i) increase the number of shares authorized thereunder and (ii) extend the term of such plan through…”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 23,254,562 for, 72,844 against, 7,290 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis ("CD&A"), and the compensation of the Company's named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission's compensation disclosure rules, including the compensation tables;

CORE LABORATORIES INC.’s own tally for this item (“3. Approving the Compensation of the Company's Executive Officers: An advisory vote on the compensation of the Company's named executive officers”): 36,411,684 for, 1,822,497 against — passed, per its Form 8-K filed May 10, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Approving the Compensation of the Company's Executive Officers : An advisory vote on the compensation of the Company's named executive officers was approved as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 70 managers: 23,004,174 for, 352,247 against, 7,290 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 212 managers: 29,112,179 for, 1,385,923 against, 1,558 abstained, 185 not voted, 3,529 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the year ending December 31, 2024;

CORE LABORATORIES INC.’s own tally for this item (“2. Appointment of KPMG as Independent Registered Public Accountant: The ratification of the appointment of KPMG as the Company's independent registered public accountant for the fiscal year ending December 31, 2024”): 40,402,356 for, 802,763 against — passed, per its Form 8-K filed May 10, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Appointment of KPMG as Independent Registered Public Accountant : The ratification of the appointment of KPMG as the Company's independent registered public accountant for the fiscal year ending December 31, 2024 was approved as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 23,299,833 for, 27,573 against, 7,290 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.